Despite being recently divested from multinational pharma giant Sanofi, Czech firm Zentiva is becoming one of the fastest-growing generics manufacturing companies in Europe, with a swathe of recent international acquisitions strengthening its position.
Zentiva, a Czech Republic-based generics manufacturer, is on a mission to expand its reach after being divested from multinational firm Sanofi. Zentiva currently has two flagship production sites in Prague and Bucharest, and its reach extends to 25 countries globally. Its focus is cardiovascular disorders, inflammatory conditions, pain, infections and diseases of the central nervous system and the gastrointestinal and urology fields.
Zentiva was acquired by Sanofi in 2008; however, after Sanofi’s decision to divest their European generics unit, Zentiva was sold to Advent International for EUR 1.9 billion in 2018. Since the divestment, Zentiva has embarked on an ambitious international expansion program, most recently acquiring the Central and Eastern European business of generics and biosimilars company Alvogen through a deal to purchase Romania-based manufacturer Labormed, which operates a 71,000-square-foot manufacturing facility in Bucharest. This acquisition grants Zentiva access to 14 key markets across the region, including Russia, Romania, Bulgaria, Hungary, Poland and the Balkans. Earlier in 2019, Zentiva acquired UK-based Creo Pharma and Solacium Pharma in Romania, as well as a manufacturing site in Ankleshwar in India. Back on the home front, Zentiva invested more than EUR 30 million in its Prague production facility.
Zentiva is led by Nick Haggar, a pharma industry veteran bringing prior experience as president of Medicines for Europe in 2014 and CEO of Insud Pharma.
